The Conscious Fund

The Conscious Fund operates as a venture capital firm, concentrating its investments on global early-stage ventures within the psychedelic medicine sector. The firm strategically backs companies developing innovative solutions to address pervasive challenges in mental health, addiction, and chronic pain, leveraging the therapeutic potential of psychedelics. Its investment approach supports the development and scaling of businesses poised to bring these novel treatments to market.

The company was founded in 2019 by Henri Sant-Cassia and Michael Hoyos. Their foundational insight recognized the burgeoning scientific interest and clinical potential of psychedelic compounds for medical applications, identifying a significant opportunity to catalyze growth in a nascent but critical industry. This initiative was born from a conviction that strategic capital could accelerate the development of groundbreaking therapeutic modalities.

The fund's primary stakeholders are the early-stage companies it finances, which are actively pioneering new frontiers in health. The Conscious Fund's overarching vision is to foster a robust ecosystem around psychedelic medicine, aiming to deliver substantially improved patient outcomes and reshape conventional approaches to mental and physical well-being through its targeted investment thesis.